Intellia Therapeutics, Inc. 4

Edward J. Dulac III, EVP and CFO of Intellia Therapeutics, Inc., sold 8,111 shares of common stock in a mandatory sell-to-cover transaction related to RSU vesting on July 22, 2026.

On July 22, 2026, Edward J. Dulac III, EVP and Chief Financial Officer of Intellia Therapeutics, Inc., executed a mandatory sell-to-cover transaction in which 8,111 shares of Intellia common stock were sold at a weighted average price of approximately $11.25 per share to satisfy tax withholding obligations arising from the vesting of restricted stock units (RSUs). This non-volitional sale generated proceeds of roughly $91,000 and left Dulac with beneficial ownership of 148,175 shares of common stock. The sale was executed in multiple trades within a price range of $11.25 to $11.28 per share and is characterized in the filing as an administrative transaction related to equity compensation rather than a discretionary reduction in exposure to the company's stock.

Filing Facts

CIK

1652130

Ticker

NTLA

Form

4

Source Type

fda

Accession

0001193125-26-316279

Alert Tier

5